Pfizer Inc. (PFE)

US — Healthcare Sector
Peers: ABBV  MRK  LLY  BMY  JNJ  AMGN  GILD 

Automate Your Wheel Strategy on PFE

With Tiblio's Option Bot, you can configure your own wheel strategy including PFE - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol PFE
  • Rev/Share 11.0067
  • Book/Share 15.9713
  • PB 1.5441
  • Debt/Equity 0.6785
  • CurrentRatio 1.2581
  • ROIC 0.0897

 

  • MktCap 139746394600.0
  • FreeCF/Share 1.9771
  • PFCF 12.4551
  • PE 17.7335
  • Debt/Assets 0.2946
  • DivYield 0.0862
  • ROE 0.0878

 

  • Rating B+
  • Score 3
  • Recommendation Neutral
  • P/E Score 2
  • DCF Score 5
  • P/B Score 4
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Initiation PFE Cantor Fitzgerald -- Neutral -- $24 April 22, 2025
Resumed PFE BofA Securities -- Neutral -- $29 Dec. 10, 2024
Initiation PFE Bernstein -- Market Perform -- $32 Oct. 17, 2024

News

July's 5 Dividend Growth Stocks With Yields Up To 7.96%
ABBV, APAM, BLK, BMY, EBF, MRK, NWE, PFE, RLJ, STT, TROW, UPS, WU
Published: July 18, 2025 by: Seeking Alpha
Sentiment: Positive

Dividend growth stocks can offer a stable way to passively grow one's income, creating long-term compounding wealth over the long run. Today, we are looking at a screening process that focuses on higher yields but ranks higher on dividend safety and consistency for growth. From the hundreds that end up listed, we take a look at some of those that rank on the higher yield end for an initial look.

Read More
image for news July's 5 Dividend Growth Stocks With Yields Up To 7.96%
3 Ultra-Safe Dividend Stocks That Yield Over 5%
NWE, PFE, UPS
Published: July 17, 2025 by: 24/7 Wall Street
Sentiment: Positive

Key Points These dividend stocks yield 5% or more.

Read More
image for news 3 Ultra-Safe Dividend Stocks That Yield Over 5%
Bristol Myers Squibb, Pfizer to sell blockbuster blood thinner Eliquis at 40% discount
BMY, PFE
Published: July 17, 2025 by: CNBC
Sentiment: Neutral

Bristol Myers Squibb and Pfizer said they will start selling their blockbuster blood thinner, Eliquis, directly to some patients at a more than 40% discount. The companies' new effort would bypass traditional middlemen, including pharmacy benefit managers and insurers, to cut the drug's monthly cost from a list price of around $606 to $346.

Read More
image for news Bristol Myers Squibb, Pfizer to sell blockbuster blood thinner Eliquis at 40% discount
Dividend Harvesting Portfolio Week 228: $22,800 Allocated, $2,399.27 In Projected Dividends
C, ENB, MO, O, PFE, QQQI
Published: July 17, 2025 by: Seeking Alpha
Sentiment: Positive

The Dividend Harvesting Portfolio is thriving, generating strong recurring income and capital appreciation, with forward dividend income nearing $2,400 and a yield over 8%. My disciplined weekly allocation and diversified approach—spanning 102 positions—have mitigated downside risk and steadily grown income, even during market uncertainty. Recent additions to Bristol Myers Squibb, BP, and BSTZ reflect my focus on undervalued, high-yield opportunities positioned for growth amid potential Fed rate cuts.

Read More
image for news Dividend Harvesting Portfolio Week 228: $22,800 Allocated, $2,399.27 In Projected Dividends
I Sold Pfizer at a 13% Loss – Here's Why I'm Choosing Stability Over Risk
PFE
Published: July 17, 2025 by: 24/7 Wall Street
Sentiment: Neutral

A Reddit poster took a big loss on Pfizer. They needed to dump some shares because they occupied a huge chunk of their portfolio.

Read More
image for news I Sold Pfizer at a 13% Loss – Here's Why I'm Choosing Stability Over Risk
Bristol Myers, Pfizer to sell blood thinner Eliquis directly to patients
BMY, PFE
Published: July 17, 2025 by: Reuters
Sentiment: Positive

US drugmakers Bristol Myers and Pfizer said on Thursday that they will make their blood thinner, Eliquis, available directly to cash-paying patients at discounted rate through a new program.

Read More
image for news Bristol Myers, Pfizer to sell blood thinner Eliquis directly to patients
Bristol-Myers Squibb and Pfizer plan to sell the widely used blood thinner Eliquis directly to patients at a discounted cash price
BMY, PFE
Published: July 17, 2025 by: WSJ
Sentiment: Positive

The joint venture is launching a direct-to-consumer service of Eliquis after discussions with the Trump administration.

Read More
image for news Bristol-Myers Squibb and Pfizer plan to sell the widely used blood thinner Eliquis directly to patients at a discounted cash price
How Will Pfizer's Oncology Drugs Perform in Q2 Earnings?
PFE
Published: July 15, 2025 by: Zacks Investment Research
Sentiment: Negative

PFE's oncology unit is in focus ahead of Q2 results, with key drugs facing both rising demand and market pressure.

Read More
image for news How Will Pfizer's Oncology Drugs Perform in Q2 Earnings?
“Nobody Ever Went Broke Taking a Profit” – Grab The Highest-Yielding S&P 500 Stocks Right Now
AES, LYB, MO, PFE, VZ
Published: July 11, 2025 by: 24/7 Wall Street
Sentiment: Positive

A Wall Street maxim states, “Twenty percent of investors who want to make money are in stocks, while the other 80 percent who want to keep their money are in bonds.

Read More
image for news “Nobody Ever Went Broke Taking a Profit” – Grab The Highest-Yielding S&P 500 Stocks Right Now
Will Pfizer (PFE) Beat Estimates Again in Its Next Earnings Report?
PFE
Published: July 11, 2025 by: Zacks Investment Research
Sentiment: Positive

Pfizer (PFE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Read More
image for news Will Pfizer (PFE) Beat Estimates Again in Its Next Earnings Report?
JNJ vs. Pfizer: Which Pharma Giant is the Better Investment Now?
JNJ, PFE
Published: July 09, 2025 by: Zacks Investment Research
Sentiment: Positive

JNJ's growth outlook, rising estimates, and strength in Innovative Medicine give it an edge over Pfizer in 2025.

Read More
image for news JNJ vs. Pfizer: Which Pharma Giant is the Better Investment Now?
Healthy Returns: Medicaid cuts in Trump's megabill may affect some drugmakers more than others
BMY, GILD, JNJ, NVO, PFE, RHHBY, VRTX
Published: July 08, 2025 by: CNBC
Sentiment: Negative

Trump's "big beautiful" bill will also affect the pharmaceutical industry, while AI startups have pulled in the majority of digital health funding this year.

Read More
image for news Healthy Returns: Medicaid cuts in Trump's megabill may affect some drugmakers more than others
Will The Tariff “Taco Trade” End The Rally? 5 High-Yield Value Stocks Are Strong Buys Now
CAG, CVX, ES, LYB, PFE
Published: July 07, 2025 by: 24/7 Wall Street
Sentiment: Neutral

Value stocks are generally companies that trade at a price lower than their fundamental value or what their performance suggests they should be worth.

Read More
image for news Will The Tariff “Taco Trade” End The Rally? 5 High-Yield Value Stocks Are Strong Buys Now
Pfizer Inc. (NYSE: PFE) Price Prediction and Forecast 2025-2030 (July 2025)
PFE
Published: July 04, 2025 by: 24/7 Wall Street
Sentiment: Positive

Shares of Pfizer ( NYSE: PFE ) surged 8.24% over the past month, reducing the stock's year-to-date loss to 5.02%.

Read More
image for news Pfizer Inc. (NYSE: PFE) Price Prediction and Forecast 2025-2030 (July 2025)
2 Stocks to Buy With Less Than $50
EXEL, PFE
Published: July 04, 2025 by: The Motley Fool
Sentiment: Positive

One formula to generate strong returns on equity markets involves investing small amounts of money in top stocks regularly over long periods. Buying fractional shares is one way to apply this strategy, but it's also possible to find attractive corporations at already-affordable prices.

Read More
image for news 2 Stocks to Buy With Less Than $50
Pfizer: Options Activity Speaks Bullish
PFE
Published: July 03, 2025 by: Seeking Alpha
Sentiment: Positive

The call activity above the current Pfizer Inc. share price, increasing call premiums, and the lack of defensive put buying point to options traders expecting Pfizer to move higher from current price. Cost-saving initiatives, strong free cash flow, and a large R&D budget, support future growth and innovation, with recent pipeline successes as catalysts. Despite macro risks and ROIC below historical averages, PFE stock's 52% upside to fair value and compelling yield make it a rare value opportunity.

Read More
image for news Pfizer: Options Activity Speaks Bullish
Pfizer Trades Above 50-Day Average for a Month: Time to Buy?
PFE
Published: July 03, 2025 by: Zacks Investment Research
Sentiment: Positive

PFE trades above its 50-day average for over a month, signaling bullish momentum despite COVID revenue declines and patent risks.

Read More
image for news Pfizer Trades Above 50-Day Average for a Month: Time to Buy?
Pfizer (PFE) Outperforms Broader Market: What You Need to Know
PFE
Published: July 02, 2025 by: Zacks Investment Research
Sentiment: Positive

In the latest trading session, Pfizer (PFE) closed at $25.32, marking a +1.12% move from the previous day.

Read More
image for news Pfizer (PFE) Outperforms Broader Market: What You Need to Know
Cannabis Lighting Market Report 2025-2030 | Share Analysis, Industry Trends & Statistics, Growth Forecasts - Pfizer Ventures into Cannabis with $6.7 Billion Deal, Boosting Industry Growth
PFE
Published: July 01, 2025 by: GlobeNewsWire
Sentiment: Neutral

The Cannabis Lighting Market is set to grow at a CAGR of 7.6% during the forecast period, driven by rising medical cannabis use and cultivation. Key players like Pfizer are entering the market. LED lights are a major trend due to energy efficiency, with North America leading. New launches by companies like OSRAM enhance growth. The Cannabis Lighting Market is set to grow at a CAGR of 7.6% during the forecast period, driven by rising medical cannabis use and cultivation. Key players like Pfizer are entering the market. LED lights are a major trend due to energy efficiency, with North …

Read More
image for news Cannabis Lighting Market Report 2025-2030 | Share Analysis, Industry Trends & Statistics, Growth Forecasts - Pfizer Ventures into Cannabis with $6.7 Billion Deal, Boosting Industry Growth
Pfizer's Strong Late-Stage Pipeline Can Drive Long-Term Growth
PFE
Published: July 01, 2025 by: Zacks Investment Research
Sentiment: Positive

PFE's robust late-stage pipeline, recent FDA wins and deep oncology bets position it for long-term growth through 2030.

Read More
image for news Pfizer's Strong Late-Stage Pipeline Can Drive Long-Term Growth
Here is What to Know Beyond Why Pfizer Inc. (PFE) is a Trending Stock
PFE
Published: July 01, 2025 by: Zacks Investment Research
Sentiment: Positive

Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Read More
image for news Here is What to Know Beyond Why Pfizer Inc. (PFE) is a Trending Stock
PFE's Hympavzi Phase III Hemophilia Study With Inhibitors Meets Goal
PFE
Published: June 27, 2025 by: Zacks Investment Research
Sentiment: Neutral

Pfizer's Hympavzi meets key phase III goals, demonstrating a significant reduction in bleeding in hemophilia patients with inhibitors.

Read More
image for news PFE's Hympavzi Phase III Hemophilia Study With Inhibitors Meets Goal
All You Need to Know About Pfizer (PFE) Rating Upgrade to Buy
PFE
Published: June 26, 2025 by: Zacks Investment Research
Sentiment: Positive

Pfizer (PFE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Read More
image for news All You Need to Know About Pfizer (PFE) Rating Upgrade to Buy
Don't Sleep On Pfizer: The Turnaround Is Just Getting Started
PFE
Published: June 25, 2025 by: Seeking Alpha
Sentiment: Positive

Despite a revenue miss, Pfizer's Q1 earnings crushed estimates due to aggressive, structural cost-cutting, signaling a powerful shift towards operational and margin excellence. Management is expanding its cost-savings program to a massive $7.7 billion by 2027, aiming to create a powerful EPS growth story despite flat revenues. Pfizer's non-COVID portfolio is firing on all cylinders, with key drugs like Nurtec and Padcev showing robust double-digit growth, proving underlying business health.

Read More
image for news Don't Sleep On Pfizer: The Turnaround Is Just Getting Started
17 Ideal 'Safer' Dividend Dogs To Buy Out Of 72 June Graham Value All-Stars
ARCC, BCS, BNS, BXSL, CALM, COLB, DHT, EPD, ET, FLNG, FSK, GBDC, HP, HTGC, ING, ITUB, JD, MO, MPLX, NOAH, NWBI, OBDC, PFE, RIO, RMR
Published: June 25, 2025 by: Seeking Alpha
Sentiment: Positive

I use YCharts' Value Score and Ben Graham Formula Value All Stars, or GASV, to identify large-cap stocks offering strong value and dividend safety. Seventeen out of twenty-four "safer" lowest-priced Dividend Dogs of the GASV are currently fair-priced and ready to buy for income investors. Top ten GASV stocks offer projected average net gains of 32.99% by June 2026, with yields ranging from 8.94% to 13.81%.

Read More
image for news 17 Ideal 'Safer' Dividend Dogs To Buy Out Of 72 June Graham Value All-Stars
Pfizer Invites Public to View and Listen to Webcast of August 5 Conference Call with Analysts
PFE
Published: June 25, 2025 by: Business Wire
Sentiment: Neutral

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. EDT on Tuesday, August 5, 2025. The purpose of the call is to provide an update on Pfizer's results, as reflected in the company's Second Quarter 2025 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.com/investors. In.

Read More
image for news Pfizer Invites Public to View and Listen to Webcast of August 5 Conference Call with Analysts
Pfizer to Face Several Headwinds: Can It Successfully Navigate Them?
PFE
Published: June 24, 2025 by: Zacks Investment Research
Sentiment: Negative

PFE faces a decline in COVID revenues, LOE pressure and IRA impacts but rising EPS estimates offer a glimmer of resilience.

Read More
image for news Pfizer to Face Several Headwinds: Can It Successfully Navigate Them?
10 'Safer' Dividend Buys Of Barron's Better Bets Than T-Bills For June
BBY, BMY, CAG, EQR, ETR, FRT, KEY, KIM, KMI, LYB, MO, O, OKE, PFE, RF, SPG, TFC, UDR, USB, VZ, WMB
Published: June 24, 2025 by: Seeking Alpha
Sentiment: Positive

Long-term bond yields continue to rise. But investors looking for income can still find plenty of attractive opportunities with dividend-paying stocks that have healthy yields. “23 stocks pay huge dividends. They should be a better bet than treasuries.” — Barron's Weekly. In Barron's, Steven Wieting, strategist at Citi Wealth, noted that a growing dividend is a tangible benefit for shareholders and a hallmark of companies with strong balance sheets. "Nobody can fake a dividend," he said.

Read More
image for news 10 'Safer' Dividend Buys Of Barron's Better Bets Than T-Bills For June
Pfizer vs BMY: Which Oncology Drugmaker Is a Better Choice for Now?
BMY, PFE
Published: June 20, 2025 by: Zacks Investment Research
Sentiment: Neutral

Pfizer's broader portfolio and higher dividend yield give it an edge over Bristol Myers in the oncology showdown.

Read More
image for news Pfizer vs BMY: Which Oncology Drugmaker Is a Better Choice for Now?
Is Trending Stock Pfizer Inc. (PFE) a Buy Now?
PFE
Published: June 20, 2025 by: Zacks Investment Research
Sentiment: Positive

Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Read More
image for news Is Trending Stock Pfizer Inc. (PFE) a Buy Now?

About Pfizer Inc. (PFE)

  • IPO Date 1972-06-01
  • Website https://www.pfizer.com
  • Industry Drug Manufacturers - General
  • CEO Albert Bourla
  • Employees 81000

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.